Aspergillosis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

Aspergillosis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

  • October 2019 •
  • 80 pages •
  • Report ID: 5823488 •
  • Format: PDF
Aspergillosis Drug pipeline report- 2020 is an annual R&D review of Aspergillosis pipeline candidates. The report presents the current status of all major Aspergillosis therapeutic compounds. Detailed insights into Aspergillosis pipeline development, current status, companies, drug profiles and Aspergillosis preclinical and clinical trials are included.

2020 Aspergillosis Pipeline Market Insights
Aspergillosis disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Aspergillosis therapies, pipeline by phase and others are included.

Aspergillosis pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Aspergillosis Therapeutic Drug candidates
Both active and inactive Aspergillosis pipeline drug candidates are included in the report

Aspergillosis Clinical Trials and preclinical Studies
Aspergillosis In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Aspergillosis pipeline market developments
Aspergillosis Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Aspergillosis pipeline companies in active development

The report analyzes Aspergillosis pipeline of the below companies-
Acea Biotech Inc, Amplyx Pharmaceuticals Inc, Astellas Pharma Inc, Basilea Pharmaceutica Ltd, Biosergen AS, Cidara Therapeutics Inc, F2G Ltd, iCo Therapeutics Inc., Matinas BioPharma, Mayne Pharma Group Ltd, Merck & Co Inc, Molecular Express Inc, Novabiotics Ltd, Pulmatrix Inc, Pulmocide Ltd, Scynexis Inc, Sealife PHARMA GMBH, Shaanxi Synthetic Pharmaceutical Co Ltd, Viamet Pharmaceuticals Inc, Vical Inc, Visterra Inc

Report Coverage
- What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

- Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

- Companies
21 Companies investing in Aspergillosis pipeline from discovery stage to pre-registration phase are included

- Drug profiles
Over 10 details of each Aspergillosis pipeline candidate are included

- Company Profiles
Business overview and contact details of all companies operating in the industry are provided

- Market Developments
News, Developments and other recent industry developments are included